CF
Cantor Fitzgerald Latest Price Targets & Analyst Ratings
| Stock | Analyst | Price | Price Target |
Upside Downside | Rating | Date | |
|---|---|---|---|---|---|---|---|
401
Rezolute
RZLT
$696M
|
PS
Pete Stavropoulos
| $8 | $5 |
38%
downside
| Overweight |
19 Sep ‘23
2 years ago |
|
402
Offerpad Solutions
OPAD
$156M
|
BK
Brett Knoblauch
| $5.11 | $18 |
252%
upside
| Overweight |
18 Sep ‘23
2 years ago |
|
403
Health Catalyst
HCAT
$238M
|
SH
Steven Halper
| $3.38 | $16 |
373%
upside
| Overweight |
14 Sep ‘23
2 years ago |
|
404
Acadia Healthcare
ACHC
$2.19B
|
JF
Joseph France
| $23.72 | $85 |
258%
upside
| Neutral |
14 Sep ‘23
2 years ago |
|
405
Editas Medicine
EDIT
$248M
|
RB
Rick Bienkowski
| $2.76 | $14 |
407%
upside
| Overweight |
13 Sep ‘23
2 years ago |
|
|
CNTB
406
Connect Biopharma Holdings Limited Ordinary Shares
CNTB
$97.5M
|
LC
Louise Chen
| $1.75 | $5 |
186%
upside
| Overweight |
13 Sep ‘23
2 years ago |
|
407
ALX Oncology
ALXO
$65.3M
|
AY
Alethia Young
| $1.22 | $18 |
1,375%
upside
| Overweight |
12 Sep ‘23
2 years ago |
|
|
ATON
408
AlphaTON Capital Corp. Common Stock
ATON
$11.6M
|
LW
Li Watsek
| $5.09 | $220 |
4,222%
upside
| Overweight |
7 Sep ‘23
2 years ago |
|
409
Fate Therapeutics
FATE
$116M
|
LW
Li Watsek
| $1.01 | $5 |
395%
upside
| Neutral |
7 Sep ‘23
2 years ago |
|
410
Curis
CRIS
$21M
|
AY
Alethia Young
| $1.68 | $60 |
3,471%
upside
| Overweight |
7 Sep ‘23
2 years ago |
|
411
Elutia
ELUT
$79.7M
|
BF
Brandon Folkes
| $1.88 | $8 |
326%
upside
| Overweight |
7 Sep ‘23
2 years ago |
|
|
IMAB
412
I-MAB
IMAB
$358M
|
LC
Louise Chen
| $4.38 | $25 |
471%
upside
| Overweight |
5 Sep ‘23
2 years ago |
|
413
HUTCHMED
HCM
$2.74B
|
LC
Louise Chen
| $15.97 | $50 |
213%
upside
| Overweight |
5 Sep ‘23
2 years ago |
|
414
Ocugen
OCGN
$322M
|
JK
Jennifer Kim
| $1.03 | $2 |
94%
upside
| Overweight |
31 Aug ‘23
2 years ago |
|
415
Outlook Therapeutics
OTLK
$41.5M
|
KK
Kristen Kluska
| $0.9350 | $20 |
2,039%
upside
| Neutral |
30 Aug ‘23
2 years ago |
|
416
Alpha Tau Medical
DRTS
$306M
|
KK
Kristen Kluska
| $3.60 | $23 |
539%
upside
| Overweight |
29 Aug ‘23
2 years ago |
|
417
Mustang Bio
MBIO
$10.4M
|
KK
Kristen Kluska
| $1.43 | $900 |
62,837%
upside
| Overweight |
24 Aug ‘23
2 years ago |
|
418
Lucid Diagnostics
LUCD
$140M
|
CD
Charles Duncan
| $1.37 | $4 |
192%
upside
| Overweight |
22 Aug ‘23
2 years ago |
|
419
Axogen
AXGN
$735M
|
TS
Travis Steed
| $15.98 | $16 |
0%
upside
| Overweight |
22 Aug ‘23
2 years ago |
|
420
Arcutis Biotherapeutics
ARQT
$2.06B
|
LC
Louise Chen
| $17.15 | $50 |
192%
upside
| Overweight |
22 Aug ‘23
2 years ago |
|
421
Xenon Pharmaceuticals
XENE
$3.02B
|
CD
Charles Duncan
| $39.21 | $58 |
48%
upside
| Overweight |
22 Aug ‘23
2 years ago |
|
422
Jazz Pharmaceuticals
JAZZ
$7.86B
|
BF
Brandon Folkes
| $129.50 | $180 |
39%
upside
| Overweight |
22 Aug ‘23
2 years ago |
|
423
Eledon Pharmaceuticals
ELDN
$162M
|
AY
Alethia Young
| $2.71 | $9 |
232%
upside
| Overweight |
22 Aug ‘23
2 years ago |
|
|
CMPS
424
Compass Pathways
CMPS
$493M
|
JF
Jonathan Fiore
| $5.14 | $21 |
309%
upside
| Overweight |
22 Aug ‘23
2 years ago |
|
425
BioVie
BIVI
$13.1M
|
CD
Charles Duncan
| $1.74 | $1,100 |
63,118%
upside
| Overweight |
22 Aug ‘23
2 years ago |
|